CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 589 enrolled
Drug / intervention
Bupropiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00063323
NCT00063323Phase 3Completed
CompareCT.gov

Maintenance Treatment for Prevention of Smoking Relapse

National Institute on Drug Abuse (NIDA)·interventional·Posted Jul 1, 2003·Updated Jan 12, 2017

In Brief

A Phase 3 clinical trial evaluating Bupropion for Tobacco Use Disorder. Completed, enrolled 589 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the efficacy and cost-effectiveness of long-term pharmacotherapy (using Zyban and/or nicotine replacement) for reducing the relapse rate associated with stopping smoking.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Use Disorder
CountriesUnited States
CollaboratorsResearch Foundation for Mental Hygiene, Inc.

Timeline

Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 1, 2003
Enrollment StartAug 1, 2000
Primary CompletionJul 1, 2006
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 23.0 years ago

Interventions

Bupropiondrug